Benchmark assumed coverage on shares of Acasti Pharma (NASDAQ:ACST) in a report released on Friday. The firm set a “buy” rating and a $7.00 price target on the biopharmaceutical company’s stock.

Separately, ValuEngine raised Acasti Pharma from a “sell” rating to a “hold” rating in a report on Monday, November 20th.

Shares of Acasti Pharma (NASDAQ:ACST) remained flat at $$1.01 during trading on Friday. 1,081,676 shares of the stock were exchanged, compared to its average volume of 451,800. Acasti Pharma has a 1 year low of $0.84 and a 1 year high of $3.36. The firm has a market capitalization of $15.06, a P/E ratio of -1.28 and a beta of 1.49.

WARNING: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/05/acasti-pharma-acst-receives-new-coverage-from-analysts-at-benchmark.html.

Acasti Pharma Company Profile

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG).

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.